Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease

A 44-year-old Japanese woman with autosomal dominant polycystic kidney disease was admitted to our hospital for evaluation of abdominal distension. Her eGFR was 53.7 mL/min/1.73 m(2). Total kidney volume was 2,614 mL. Tolvaptan (60 mg/day) was started to treat renal involvement. The patient's a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Hiroki, Hoshino, Junichi, Suwabe, Tatsuya, Sumida, Keiichi, Sekine, Akinari, Oshima, Yoichi, Oguro, Masahiko, Kunizawa, Kyohei, Kawada, Masahiro, Hiramatsu, Rikako, Hayami, Noriko, Hasegawa, Eiko, Yamanouchi, Masayuki, Sawa, Naoki, Takaichi, Kenmei, Ubara, Yoshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624279/
https://www.ncbi.nlm.nih.gov/pubmed/29034246
http://dx.doi.org/10.1159/000477664
Descripción
Sumario:A 44-year-old Japanese woman with autosomal dominant polycystic kidney disease was admitted to our hospital for evaluation of abdominal distension. Her eGFR was 53.7 mL/min/1.73 m(2). Total kidney volume was 2,614 mL. Tolvaptan (60 mg/day) was started to treat renal involvement. The patient's abdominal fullness began to improve and liver volume, indicating advanced polycystic liver disease (PLD), decreased from 9,750 mL to 8,345 mL after 17 months of tolvaptan treatment, though there was no significant change in kidney volume. This case indicates that tolvaptan may be a therapeutic option for hepatomegaly in patients with symptomatic PLD.

Ejemplares similares